Literature DB >> 8064798

Substituted 1,3-dipropylxanthines as irreversible antagonists of A1 adenosine receptors.

P J Scammells1, S P Baker, L Belardinelli, R A Olsson.   

Abstract

This report describes the synthesis of 29 xanthines containing a chemoreactive chloroaryl, beta-chloroethylamino, alpha,beta-unsaturated carbonyl, bromoacetyl, 3-(fluorosulfonyl)benzoyl, or 4-(fluorosulfonyl)benzoyl group as part of an exocyclic 1-, 3-, or 8-substituent. The xanthines inhibited the binding of [3H]-8-cyclopentyl-1,3-dipropylxanthine ([3H]CPX) to the A1 adenosine receptor (A1AR) of DDT1 MF2 cells at IC50s in the low-nanomolar to low-micromolar range. Seven of the 29 analogues irreversibly inhibited the binding of [3H]CPX without changing the KD of that ligand; five were 1,3-dipropylxanthines having the following reactive groups as 8-substituents: (bromoacetamido)methyl (24), (bromoacetamido)ethyl (25), (bromoacetamido)propyl (26), [4-(fluorosulfonyl)benzamido]methyl (33) or 3-[[4-(fluorosulfonyl)benzoyl]oxy]cyclopentyl (42). Both 8-cyclopentyl-3-[3-[[4- (fluorosulfonyl)benzoyl]oxy]propyl]-1-propylxanthine (53) and 8-cyclopentyl-1,3-bis[3-[[4- (fluorosulfonyl)benzoyl]oxy]propyl]xanthine (55) inhibited [3H]CPX binding irreversibly. Five of the ligands, including 26, 33 (IC50 = 49 microM), and 53 (IC50 = 9 microM), antagonized the binding of [3H]NECA to the A2aAR of PC12 cells, but unlike binding to the A1AR, binding to the A2aAR was completely reversible. The potency of 33 (IC50 = 2 microM, 72% loss of CPX binding at 1 microM) and 53 (IC50 = 0.01 microM, 74% loss of CPX binding at 0.05 microM) and their selectivity for the A1AR suggest that those two ligands may be useful in studies of the structure and function of that receptor.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8064798     DOI: 10.1021/jm00043a010

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  13 in total

1.  Tonic activity of the rat adipocyte A1-adenosine receptor.

Authors:  Hui-Xiu Liang; Luiz Belardinelli; Mark J Ozeck; John C Shryock
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

Review 2.  Xanthines as adenosine receptor antagonists.

Authors:  Christa E Müller; Kenneth A Jacobson
Journal:  Handb Exp Pharmacol       Date:  2011

3.  Structure-activity relationships of new 1H-imidazo[4,5-c]quinolin-4-amine derivatives as allosteric enhancers of the A3 adenosine receptor.

Authors:  Anikó Göblyös; Zhan-Guo Gao; Johannes Brussee; Roberto Connestari; Sabrina Neves Santiago; Kai Ye; Adriaan P Ijzerman; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2006-06-01       Impact factor: 7.446

4.  Physical Characterization of 1,3-dipropyl-8-cyclopentylxanthine (CPX).

Authors:  Timothy McPherson; Rahul V Manek; William Kolling; Sihui Long; Tonglei Li
Journal:  AAPS PharmSciTech       Date:  2010-05-04       Impact factor: 3.246

5.  Functionalized congeners of P2Y1 receptor antagonists: 2-alkynyl (N)-methanocarba 2'-deoxyadenosine 3',5'-bisphosphate analogues and conjugation to a polyamidoamine (PAMAM) dendrimer carrier.

Authors:  Sonia de Castro; Hiroshi Maruoka; Kunlun Hong; S Michael Kilbey; Stefano Costanzi; Béatrice Hechler; Garth G Brown; Christian Gachet; T Kendall Harden; Kenneth A Jacobson
Journal:  Bioconjug Chem       Date:  2010-07-21       Impact factor: 4.774

6.  Differential A(1)-adenosine receptor reserve for inhibition of cyclic AMP accumulation and G-protein activation in DDT(1) MF-2 cells.

Authors:  S P Baker; P J Scammells; L Belardinelli
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

7.  Persistent activation by and receptor reserve for an irreversible A1-adenosine receptor agonist in DDT1 MF-2 cells and in guinea pig heart.

Authors:  J Zhang; L Belardinelli; K A Jacobson; D H Otero; S P Baker
Journal:  Mol Pharmacol       Date:  1997-09       Impact factor: 4.436

Review 8.  Functionalized congener approach to the design of ligands for G protein-coupled receptors (GPCRs).

Authors:  Kenneth A Jacobson
Journal:  Bioconjug Chem       Date:  2009-04-30       Impact factor: 4.774

9.  Mass spectrometry-based ligand binding assays on adenosine A1 and A2A receptors.

Authors:  A Massink; M Holzheimer; A Hölscher; J Louvel; D Guo; G Spijksma; T Hankemeier; A P IJzerman
Journal:  Purinergic Signal       Date:  2015-10-19       Impact factor: 3.765

10.  FSCPX, a Chemical Widely Used as an Irreversible A₁ Adenosine Receptor Antagonist, Modifies the Effect of NBTI, a Nucleoside Transport Inhibitor, by Reducing the Interstitial Adenosine Level in the Guinea Pig Atrium.

Authors:  Tamas Erdei; Adrienn Monika Szabo; Nora Lampe; Katalin Szabo; Rita Kiss; Judit Zsuga; Csaba Papp; Akos Pinter; Andras Jozsef Szentmiklosi; Zoltan Szilvassy; Bela Juhasz; Rudolf Gesztelyi
Journal:  Molecules       Date:  2018-08-30       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.